Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Endoscopic Retrograde Cholangiopancreatography Access and Complication Rates After Cholecystectomy With Common Bile Duct Stones

8. juni 2026 oppdatert av: Camilla Runfors, Karolinska Institutet

Complication Rates Associated With Access or Not to Endoscopic Retrograde Cholangiopancreatography (ERCP) in Units Performing Cholecystectomy, When Common Bile Duct Stones Are Detected on Intraoperative Cholangiography

The aim of this retrospective, register-based study is to investigate whether access, or no access, to endoscopic retrograde cholangiopancreatography (ERCP) at a surgical unit is associated with the risk of complications in patients undergoing laparoscopic cholecystectomy with common bile duct stones detected on intraoperative cholangiography.

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Detaljert beskrivelse

Annually, approximately 15,000 cholecystectomies are performed in Sweden. Cholecystectomy is indicated if gallstones cause recurrent biliary colic or complications. Gallstones can pass from the gallbladder into the common bile duct. Common bile duct stones (CBDS) can potentially cause biliary obstruction, cholangitis and pancreatitis.

Intraoperative cholangiography (IOC) during cholecystectomy is performed as a standard in Swedish surgical units. The arguments for routine IOC are several; routine IOC is associated with reduced risk of bile duct injury in patients with previous or ongoing cholecystitis, early detection of bile duct injury has been suggested to improve survival, and CBDS found by IOC, even small ones <4 mm, are associated with increased risk of complications and need for unplanned endoscopic retrograde cholangiopancreatography (ERCP) if no effort is made to clear the common bile duct.

American guidelines suggest performing IOC as a routine in adult patients undergoing laparoscopic cholecystectomy. Many countries do not practice routine IOC because it prolongs cholecystectomy and the evidence supporting its use is considered insufficient. European guidelines do not include routine IOC as a recommendation. On the other hand, both American and European guidelines advocate treatment of all CBDS, symptomatic or not.

CBDS represent a well-recognized clinical dilemma, especially when encountered first on IOC during cholecystectomy. In those situations, intraoperative treatment of CBDS has not been planned in advance.

There are several different approaches to remove CBDS. Worldwide, the two most common methods used are preoperative endoscopic retrograde cholangiopancreatography (ERCP) followed by cholecystectomy, or laparoscopic exploration of the common bile duct during cholecystectomy. In Sweden, the predominant treatment strategy for CBDS encountered on IOC is intraoperative ERCP.

The ERCP procedure itself is associated with a non-negligible risk of complications. The most common, and potentially severe, complication is post-ERCP pancreatitis (PEP). According to observational studies based on data from the Swedish Registry for Gallstone Surgery and ERCP (GallRiks), rendezvous-ERCP is associated with less complications, mainly PEP, compared to postoperative rendezvous-ERCP, and rendezvous-ERCP reduces the risk of PEP compared to conventional ERCP.

There are major differences between Swedish regions in the treatment of gallstone disease and outcome, probably because of different local routines. All units in Sweden performing cholecystectomies must be able to handle CBDS encountered at IOC, according to the national guidelines. The same guidelines advocate intraoperative ERCP with the rendezvous technique. ERCP volumes differ greatly between different surgical units in Sweden and the proportion of units performing ERCP has decreased over time. Smaller volumes of ERCP per surgeon are associated with more complications, including PEP.

In Sweden, part of the gallbladder surgery has moved from emergency care hospitals to elective, and sometimes private units, over the last few decades. Some of these units lack the equipment or expertise necessary for ERCP. Thus, despite what current national guidelines recommend, patients undergoing cholecystectomy, with a finding of CBDS on IOC, do not have the option to be treated with intra- or postoperative ERCP in such a surgical unit. Their CBDS must be treated in another way intraoperatively or with postponed ERCP after transfer to another unit.

How these structural differences in ERCP access at cholecystectomy affect the type of treatment of CBDS, time to treatment of CBDS, and thus complications, is not investigated. Because alternative treatment strategies to ERCP are used in units without access to ERCP, but also in units with access to ERCP, this question cannot simply be answered by the difference in complications from intra- and postoperative ERCP. Furthermore, these other strategies do not necessarily have a higher risk of complications compared to ERCP.

In a previous study, based on data from GallRiks, laparoscopic cholecystectomy with intraoperative rendezvous ERCP was associated with more complications compared to laparoscopic cholecystectomy with transcystic stent and postoperative ERCP.

The intention is to study how access to ERCP in different units affect complication rates in patients undergoing cholecystectomy when CBDS are detected on IOC. If the study shows no difference in risk of complications, there is a future possibility to transfer more gallbladder surgery out of emergency care hospitals and to enable more capacity for emergency surgery. On the other hand, if the study shows an increased risk of complications if the procedure is performed in a surgical unit without access to ERCP, there is an argument to transfer patients the other way around or establish capacity for ERCP at a greater number of hospitals.

Research question In patients undergoing laparoscopic cholecystectomy with CBDS on IOC, is there a difference in complication rates depending on access or not to ERCP at the surgical unit?

Aim and hypothesis The aim of this retrospective, register-based study is to investigate whether access, or no access, to ERCP at a surgical unit is associated with the risk of complications in patients undergoing laparoscopic cholecystectomy with CBDS detected on IOC.

The hypothesis is that laparoscopic cholecystectomy with CBDS on IOC in units with access to ERCP will be associated with less complications compared to units without access to ERCP.

PICO P Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with CBDS detected on IOC in Sweden 2015-2025 and registered in GallRiks.

I There is no specific intervention performed in each group. Instead, patients undergoing cholecystectomy at a unit without access to ERCP are considered as exposed individuals.

C Patients undergoing cholecystectomy at a unit with access to ERCP are considered unexposed, serving as controls.

O Primary outcome is complications within 30 days. Complications from both the cholecystectomy and the ERCP, if performed, will be considered since the entire course of care is important from a safety perspective.

Data will be analyzed separately for acute and elective gallbladder procedures, as units without access to ERCP perform elective surgery to a very large extent.

Sweden has a distinctive approach to manage CBDS, and a nationwide register for gallbladder surgery and ERCP, GallRiks. When validated, GallRiks has shown high completeness and high correctness of entered data. Taken together, this provides a unique possibility to contribute to research in gallbladder surgery.

Primary outcome Complications

Secondary outcomes Length of hospital stay, time from surgery to first treatment of common bile duct stones, unplanned ERCP after surgery due to CBDS, mortality

Studietype

Observasjonsmessig

Registrering (Antatt)

10000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with common bile duct stones detected on intraoperative cholangiography in Sweden 2015-2025 and registered in GallRiks.

Beskrivelse

Inclusion Criteria:

  • ≥18 years old
  • Laparoscopic cholecystectomy with common bile duct stones (CBDS) detected on intraoperative cholangiography (IOC)
  • Procedure registered in the Swedish Registry for Gallstone Surgery and ERCP (GallRiks) 2015-2025

Exclusion Criteria:

  • Open surgery
  • Conversion to open surgery
  • Transgastric ERCP

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Cholecystectomy without access to endoscopic retrograde cholangiopancreatography (ERCP)
Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with CBDS detected on IOC in Sweden 2015-2025 and registered in GallRiks. The cholecystectomy is performed in a unit without access to ERCP.
The exposed group consists of patients undergoing laparoscopic and diagnosed with CBDS during cholecystectomy at a unit where ERCP is not available.
Cholecystectomy with access to ERCP
Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with CBDS detected on IOC in Sweden 2015-2025 and registered in GallRiks. The cholecystectomy is performed in a unit with access to ERCP.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Complications
Tidsramme: 0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP
Overall complications from both the cholecystectomy and the endoscopic retrograde cholangiopancreatography (ERCP).
0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Length of hospital stay
Tidsramme: 0-100 days from the cholecystectomy, 0-100 days from any performed ERCP
Length of hospital stay for cholecystecomy plus ERCP
0-100 days from the cholecystectomy, 0-100 days from any performed ERCP
Time from cholecystectomy to first treatment of common bile duct stones
Tidsramme: 0-100 days from the cholecystectomy
Time from cholecystectomy to first treatment of common bile duct stones (days)
0-100 days from the cholecystectomy
Unplanned ERCP after surgery due to CBDS
Tidsramme: 1-365 days
Unplanned ERCP after treatment of CBDS
1-365 days
Unplanned readmission
Tidsramme: 0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP
Unplanned readmission (yes or no)
0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP
Mortality
Tidsramme: 0-30 days from the cholecystectomy, 0-30 days from any performed ERCP
Mortality
0-30 days from the cholecystectomy, 0-30 days from any performed ERCP

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. august 2026

Primær fullføring (Antatt)

1. oktober 2026

Studiet fullført (Antatt)

1. april 2029

Datoer for studieregistrering

Først innsendt

21. mai 2026

Først innsendt som oppfylte QC-kriteriene

8. juni 2026

Først lagt ut (Faktiske)

10. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026-02132-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere